efalizumab, Raptiva

Discontinued Warning Icon Please Note: This Drug has been discontinued.

Pharmacy Author: Emmanuel Saltiel, Pharm. D.
Medical Editor: Jay Marks, M.D.

GENERIC NAME: efalizumab

BRAND NAME: Raptiva

DRUG CLASS AND MECHANISM: Efalizumab is a synthetic (man-made) antibody that is used for the treatment of psoriasis.

Psoriasis is a disease of the skin in which the cells of the skin reproduce more rapidly than normal. This increased reproduction is thought to be stimulated by activation of the immune system, in particular, the lymphocytes. In order for lymphocytes to become activated, they must adhere (attach) to other cells through receptors on their surface. Efalizumab blocks one of these receptors (called leukocyte function antigen-1 or LFA-1) on the lymphocyte. By blocking adhesion, efalizumab prevents the activation of lymphocytes that is responsible for psoriasis.

GENERIC: No

PRESCRIPTION: Yes

PREPARATIONS: Vial of 125 mg lyophilized (freeze-dried) powder, prefilled syringe containing sterile water for reconstitution, and syringes and needles for injection.

STORAGE: Efalizumab must be stored at refrigerated temperature, between 2 and 8°C (36-46°F). Reconstituted efalizumab must be used within eight hours. Keep this medicine - as well as all others - away from the reach of children.



Report Problems to the Food and Drug Administration

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

Pill Finder Tool

Need help identifying pills and medications?
Use the pill identifier tool on RxList.


Back to Medications Index